Onconova Therapeutics (NASDAQ:ONTX) is set to announce its earnings results before the market opens on Tuesday, March 26th. Analysts expect the company to announce earnings of ($1.09) per share for the quarter.
NASDAQ:ONTX opened at $4.26 on Monday. Onconova Therapeutics has a one year low of $1.69 and a one year high of $15.30. The stock has a market cap of $24.17 million, a P/E ratio of -0.11 and a beta of 2.86.
Several equities research analysts recently commented on ONTX shares. Maxim Group set a $16.00 price objective on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 3rd. HC Wainwright set a $25.00 price objective on shares of Onconova Therapeutics and gave the stock a “buy” rating in a research note on Monday, December 3rd. ValuEngine upgraded shares of Onconova Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, January 2nd. Finally, Zacks Investment Research downgraded shares of Onconova Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, January 16th.
A hedge fund recently bought a new stake in Onconova Therapeutics stock. Dimensional Fund Advisors LP bought a new position in Onconova Therapeutics Inc (NASDAQ:ONTX) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 13,086 shares of the biopharmaceutical company’s stock, valued at approximately $28,000. Dimensional Fund Advisors LP owned approximately 0.23% of Onconova Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 49.88% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Onconova Therapeutics (ONTX) Set to Announce Earnings on Tuesday” was originally posted by Zolmax and is the property of of Zolmax. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://zolmax.com/investing/onconova-therapeutics-ontx-set-to-announce-earnings-on-tuesday/2988386.html.
About Onconova Therapeutics
Onconova Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS.
Further Reading: Net Margin – Understanding the Different Kinds of Profit
Receive News & Ratings for Onconova Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Onconova Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.